Molecular Cytogenetics Market Size, Share and Growth Forecast

A number of factors, such as the soaring cases of cancer, increasing implementation of pharmacogenomics (PGx) for drug development and disease management, rising number of technological developments in molecular cytogenetics, surging application of this technique in crop improvement, burgeoning geriatric population, and growing prevalence of genetic illnesses, will help the molecular cytogenetics market witness a CAGR of 9.9% during the forecast period (2018–2023). The market revenue stood at $1.8 billion in 2017, and it is projected to reach $3.3 billion by 2023.

The rising cases of cancer and genetic disorders will catalyze the market growth. The World Health Organization (WHO) estimates that 1.09 million, 1.20 million, 1.41 million, 1.93 million, 2.21 million, and 2.26 million new cases of stomach cancer, skin (non-melanoma) cancer, prostate cancer, colon and rectum cancer, lung cancer, and breast cancer, respectively, were diagnosed in 2020. Furthermore, the WHO reveals that lung cancer, colon and rectum cancer, liver cancer, stomach cancer, and breast cancer accounted for 1.80 million, 935,000, 830,000, 769,000, and 685,000 deaths, respectively, in 2020.

In addition, the increasing implementation of PGx for disease management and drug development will supplement the molecular cytogenetics market growth in the forecast years. Advancements in PGx have resulted in extensive studies on the genetic basis for interindividual variations in drug responses. The unearthing of such variations will lead to the development of personalized treatments. Furthermore, the United States Food and Drug Administration (USFDA)’s approval to mention pharmacogenetic test information on the labels of certain drugs will lead to the market growth.

The technology segment of the molecular cytogenetics market is classified into karyotyping, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). Among these, the FISH category is expected to demonstrate the fastest growth during the forecast period due to the increasing application of this technology in the diagnosis and prognosis of diseases and rising advancements in it. Furthermore, the CGH category is divided into standard CGH and array-based CGH. Of these, the array-based CGH category generated the higher revenue in 2017.

According to P&S Intelligence, North America accounted for the largest share in the molecular cytogenetics market in 2017. This was due to the surging incidence of genetic disorders and cancer and the increasing adoption of technologically advanced platforms, such as next-generation array and sequencing technologies. For instance, the Cancer Atlas reveals that approximately 1.9 million new cancer cases and 693,000 cancer-related deaths were recorded in North America in 2018. Additionally, the presence of advanced healthcare infrastructure in the region contributed to the market growth.

Whereas, the Asia-Pacific (APAC) molecular cytogenetics market will witness the fastest growth throughout the forecast period due to the presence of a vast population, entry of global players offering cytogenetic testing solutions, and presence of an unexplored market in the region. Besides, the soaring number of government initiatives in the form of funding, training programs, and testing programs for researchers working in the field of cytogenetics will catalyze the market growth in the region.

Thus, the increasing cancer cases and rising implementation of PGx in drug development and disease management will supplement the market growth.

Access Report Summary on Molecular Cytogenetics Market Global Industry Analysis

Article source: https://article-realm.com/article/Finance/32905-Molecular-Cytogenetics-Market-Size-Share-and-Growth-Forecast.html